Shares of Opthea Ltd. (OPT) touched a 52-week high of $5.90 last week, signaling growing investor optimism as the company approaches key phase III clinical trial milestones in the coming months.
Australia-based Opthea is a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases. Its lead investigational product is Sozinibercept, a novel, first-in-class VEGF C/D inhibitor to prevent blood vessel growth and vascular leakage in the retina and deliver superior visual outcomes in wet AMD patients when combined with any standard-of-care anti-VEGF A therapy.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.